Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) EPS (Weighted Average and Diluted) (2019 - 2025)

BioRestorative Therapies (BRTX) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.33 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 153.85% year-over-year to -$0.33, compared with a TTM value of -$1.47 through Sep 2025, down 2.8%, and an annual FY2024 reading of -$1.16, up 53.04% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.33 for Q3 2025 at BioRestorative Therapies, down from -$0.3 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.9 in Q2 2022 and bottomed at -$20.62 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$2.11, with a median of -$0.49 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 1236092.66% in 2021, then soared 126.0% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$4.4 in 2021, then skyrocketed by 106.37% to $0.28 in 2022, then tumbled by 267.86% to -$0.47 in 2023, then soared by 57.45% to -$0.2 in 2024, then crashed by 65.0% to -$0.33 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BRTX at -$0.33 in Q3 2025, -$0.3 in Q2 2025, and -$0.64 in Q1 2025.